Acquisition - March 25, 2015
Novo Sells Autoimmune Program
Novo Nordisk has sold one of its early-stage autoimmune research programs to Bristol-Myers Squibb for an undisclosed amount. As part of the agreement, Bristol-Myers obtains the exclusive rights to a discovery-stage biologics program that targets the innate immune system, which is the body’s first line of defense against infection. Novo’s program was striving to treat […]